- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Evan Diamond
News 15 results
In the News · Source: Law360
January 6, 2021
Evan Diamond comments on President Trump signing into law a bill that updates U.S. Food and Drug Administration regulations on patents for drugs
In the News · Source: Law360
October 7, 2020
Evan Diamond discusses the Federal Circuit’s decision to revive a $235M induced infringement verdict against Teva
Recognition
June 17, 2020
King & Spalding IP Practices and Individuals Recognized in the IAM Patent 1000 Guide
In the News · Source: Law360
June 2, 2020
Gerald Flattmann, Lori Gordon, Vanessa Yen and Evan Diamond advise Alexion on its patent settlement with Amgen
Events 5 results
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Webinar
October 28, 2020
Testing the Limits: New Developments in Antitrust Targeting Biologics/Biosimilars Competition
Conference
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
Speaking Engagement
June 24, 2019
Evan Diamond, Vanessa Yen to Speak at ACI’s 2019 Summit on Biosimilars
Insights 12 results
Client Alert
April 7, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?
Client Alert
Client Alert
February 12, 2021
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where are we now?
Article · Source: Law360
February 3, 2021
Challenging Therapeutics IP After Fed. Circ. Drink Can Ruling